ST目药
(600671)
| 流通市值：16.41亿 | | | 总市值：16.42亿 |
| 流通股本：1.22亿 | | | 总股本：1.22亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 52,293,464.92 | 217,295,933.69 | 124,680,446.71 | 59,548,398.28 |
| 营业收入 | 52,293,464.92 | 217,295,933.69 | 124,680,446.71 | 59,548,398.28 |
| 二、营业总成本 | 49,169,104.63 | 188,884,737.6 | 129,724,584.88 | 84,573,860.37 |
| 营业成本 | 30,883,717.3 | 114,341,630.46 | 71,362,825.86 | 43,458,675.67 |
| 税金及附加 | 541,505.5 | 1,904,009.69 | 973,931.35 | 404,123.5 |
| 销售费用 | 2,303,031.06 | 8,229,385.95 | 4,464,595.57 | 4,554,216.37 |
| 管理费用 | 14,139,528.62 | 58,005,802.1 | 47,406,264.16 | 31,789,446.65 |
| 研发费用 | - | 1,206,796.12 | 106,796.12 | 106,796.12 |
| 财务费用 | 1,301,322.15 | 5,197,113.28 | 5,410,171.82 | 4,260,602.06 |
| 其中:利息费用 | 1,324,382.84 | 5,560,910.1 | 5,298,591.54 | 4,223,004.23 |
| 其中:利息收入 | 31,187.78 | 454,255.27 | 351,201.62 | 262,490.84 |
| 加:投资收益 | - | 28,842.06 | 28,842.06 | 28,842.06 |
| 资产处置收益 | - | 12,684.84 | -137,260.06 | - |
| 资产减值损失(新) | 279,255.79 | -2,470,893.55 | 115,516.33 | 115,516.33 |
| 信用减值损失(新) | -270,579.72 | -1,469,149.84 | -2,643,053.74 | 170,329.04 |
| 其他收益 | 82,266.69 | 600,538.97 | 374,534.39 | 264,259.5 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 3,215,303.05 | 25,113,218.57 | -7,305,559.19 | -24,446,515.16 |
| 加:营业外收入 | 1,454,628.78 | 8,790,650.76 | 4,931,772.57 | 3,940,042.17 |
| 减:营业外支出 | 99,412.33 | 4,831,673.54 | 1,254,008.67 | 875,550.78 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 4,570,519.5 | 29,072,195.79 | -3,627,795.29 | -21,382,023.77 |
| 减:所得税费用 | 1,659,756.6 | 7,207,141.02 | 133,270.88 | -2,495,443.63 |
| 六、净利润 | 2,910,762.9 | 21,865,054.77 | -3,761,066.17 | -18,886,580.14 |
| 持续经营净利润 | 2,910,762.9 | 21,865,054.77 | -3,761,066.17 | -18,886,580.14 |
| 归属于母公司股东的净利润 | 5,094,308.04 | 15,245,827.73 | -3,695,546.06 | -18,500,728.95 |
| 少数股东损益 | -2,183,545.14 | 6,619,227.04 | -65,520.11 | -385,851.19 |
| (一)基本每股收益 | 0.04 | 0.13 | -0.03 | -0.15 |
| (二)稀释每股收益 | 0.04 | 0.13 | -0.03 | -0.15 |
| 九、综合收益总额 | 2,910,762.9 | 21,865,054.77 | -3,761,066.17 | -18,886,580.14 |
| 归属于母公司股东的综合收益总额 | 5,094,308.04 | 15,245,827.73 | -3,695,546.06 | -18,500,728.95 |
| 归属于少数股东的综合收益总额 | -2,183,545.14 | 6,619,227.04 | -65,520.11 | -385,851.19 |
| 公告日期 | 2025-04-28 | 2025-04-01 | 2024-10-30 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |